Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orvepitant in PTSD
NCT01000493Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Orvepitant 60 mg with Placebo (2 arms). Primary endpoint: Change From Baseline in the 17-item Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS) Total Severity Score at 12 weeks. Started Nov 2009; status: completed.
02
Drugs
orvepitant
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT01000493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000493.